Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Isocitrate dehydrogenase 1 and 2 (IDH 1/2) mutations are key drivers in chondrosarcoma, a rare mesenchymal tumor.
• Mutant IDH 1/2 produces D-2-hydroxyglutarate (D-2HG), a metabolite that inhibits α-ketoglutarate (α-KG) dependent enzymes.

Purpose of the Study:

• To review the molecular mechanisms of chondrosarcoma development, focusing on IDH mutations and epigenetic dysregulation.
• To highlight the role of non-coding RNAs (ncRNAs) in chondrosarcoma pathogenesis and their interaction with epigenetic regulators.

Main Methods:

• Review of existing literature on IDH mutations, D-2HG production, and epigenetic alterations in chondrosarcoma.
• Analysis of the role of α-KG-dependent enzymes, including TET and Jumonji families, in regulating DNA methylation and histone modification.
• Examination of the involvement of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in chondrosarcoma progression.

Main Results:

• IDH mutations lead to D-2HG accumulation, causing aberrant DNA methylation and histone modifications by inhibiting TET and Jumonji enzymes.
• ncRNAs, including miRNAs and lncRNAs, interact with α-KG-dependent epigenetic regulators, contributing to malignant transformation.
• These interactions disrupt cellular signaling pathways, promoting the development of aggressive cellular traits in chondrosarcoma.

Conclusions:

• IDH mutations and subsequent D-2HG production are central to the epigenetic reprogramming in chondrosarcoma.
• ncRNAs play a critical oncogenic role by modulating epigenetic landscapes in conjunction with genetic mutations.
• Understanding these complex genetic, epigenetic, and ncRNA interactions is crucial for developing targeted therapies for chondrosarcoma.